CHEYNEY, PA — Navrogen, Inc. has announced groundbreaking advancements in monoclonal antibody (mAb) and antibody-drug conjugate (ADC) development to target cancers that overexpress the humoral immunosuppressive oncology (HIO) factor ICAM-1. The findings, detailed in a newly published study in the European Journal of Immunology, are poised to revolutionize therapies for challenging oncology cases.
ICAM-1, a tumor-produced factor, is known to hinder the effectiveness of mAb and ADC treatments. It interferes with the immune response by binding to the IgG1 CH3 domain, suppressing critical mechanisms like complement-mediated tumor killing and antibody-dependent cellular cytotoxicity. Additionally, ICAM-1 weakens ADC therapeutic efficacy by blocking internalization into target cells.
Navrogen’s proprietary Block-Removed Immunoglobulin Technology (BRITE) platform addresses these barriers by modifying a consensus motif within the IgG1 CH3 domain. This engineering process creates antibodies that resist ICAM-1’s immunosuppressive effects, ultimately enhancing their therapeutic performance. The BRITE platform is not only enhancing Navrogen’s oncology pipeline but is also being leveraged to improve the performance of existing approved antibody-based therapies.
“The results of this study represent a significant step toward overcoming ICAM-1’s detrimental impact on antibody therapies,” noted a spokesperson from Navrogen. “By neutralizing these effects, we are able to unlock the full potential of mAb and ADC treatments, offering renewed hope to patients with cancers driven by this immunosuppressive factor.”
Navrogen will share additional insights from this research at the American Association of Cancer Research (AACR) Annual Meeting on April 29. The presentation, part of poster session 36, will spotlight how the BRITE platform can transform oncology treatment strategies.
This novel approach underscores Navrogen’s commitment to innovation in cancer therapeutics, setting the stage for improved patient outcomes and expanded possibilities in antibody-based treatment applications. The company’s advancements signal a new era in addressing unmet needs in oncology care.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.